Meet Laura | Pradaxa® Patient Profiles | Boehringer Ingelheim

Meet Laura

  • 79 years old
  • Active grandmother
    6 grandchildren keep her busy!
  • Recently diagnosed with nonvalvular
    atrial fibrillation (NVAF).
    Her cousin takes apixaban
    but Laura wants to know more about all of her
    treatment options

How will you counsel Laura
on her options?

Scroll to
find out

Laura is interested in discussing a
lower risk of bleeding

In a real-world, observational analysis, Pradaxa® 110 mg had a lower risk of
any bleeding vs warfarin while apixaban 2.5 mg and rivaroxaban 15 mg were
associated with a similar risk vs warfarin (n=55,644)
‘In a real-world analysis, Pradaxa 110mg has a lower risk of any bleeding vs Warfarin’

Not a head-to-head study; this was a real-world, observational analysis comparing the effectiveness and safety of Pradaxa® 110 mg, rivaroxaban 15 mg, and apixaban 2.5 mg vs warfarin.

Hazard ratios for additional bleeding outcomes: major bleeding=Pradaxa® 0.87 (0.75 to 1.10), apixaban 1.04 (0.76 to 1.43), rivaroxaban 1.17 (0.94 to 1.45); haemorrhagic
stroke=Pradaxa® 0.46 (0.29 to 0.72), apixaban 0.59 (0.34 to 1.02), rivaroxaban 0.68 (0.30 to 1.53).

Laura will thank you for prescribing the
most studied low-dose NOAC

Pradaxa® 110 mg has been studied in more patients than
both rivaroxaban and apixaban
‘Pradaxa is the most studied low-dose Novel Oral Anticoagulant’

Life Happens

If Laura ever needs it, Praxbind® provides the reassurance of specific, immediate, and complete reversal of Pradaxa®

  • Dual indication—for life-threatening or uncontrolled bleeding and emergency surgery/urgent procedures5

  • Specific binding allows for immediate and complete reversal of Pradaxa® with no procoagulant effects5

  • Easy to use—1 ready-to-use dose for ALL Pradaxa® patients5

  • Widely available—8,300+ sites in 48 countries6

  • References:
  • 1. Nielsen PB et al. BMJ. 2017;356:j510.
  • 2. Connolly SJ et al. N Engl J Med. 2009;361(12):1139-1151.
  • 3. Fox KAA et al. Eur Heart J. 2011;32(19):2387-2394.
  • 4. Granger CB et al. N Engl J Med. 2011;365(11):981-992.
  • 5. Praxbind® (idarucizumab) Summary of Product Characteristics. 2018.
  • 6. Data on file, Boehringer Ingelheim.